Developer docs
API playgroundTry for free, no card

Search company profiles

Concerto Biosciences

Full company profile

uuid0000bah

Namestring
Concerto Biosciences
Legal namestring
Concerto Biosciences, Inc.
Websiteurl
concertobio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Concerto Biosciences is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts, that measures, maps, and engineers microbial communities to develop therapies and consumer products across human health, food, and agricultural applications. The company's core asset is its integrated discovery platform comprising kChip, a patented MIT/Broad Institute-originated microwell array that physically constructs and measures millions of miniature microbial communities in parallel, and kAI, a proprietary artificial intelligence model trained on kChip-generated datasets to predict the behavior of untested microbial combinations. Together the platform has produced 40M+ microbial community measurements — including the 33M+ datapoint Skin Universe Project — forming the largest empirical microbial interaction dataset publicly described.

The company operates three product streams: ENS-002, a topical three-strain live biotherapeutic for atopic dermatitis that received FDA IND clearance in June 2024 and reported positive Phase 1b topline results in October 2025 (commercialized through partner Fermata Dermatologics); ENS-003, a discovery-stage live microbial candidate for recurrent vaginal yeast infection; and the CB-0XX consumer skin health ingredient portfolio addressing malodor, barrier strength, acne, and dandruff. Co-discovery and co-development agreements with partners such as Sacco System (food applications, signed January 2026) and Fermata Dermatologics (therapeutic development) provide commercial reach into consumer and biopharmaceutical channels.

Concerto's business model is a partnership-driven B2B platform play: revenue is expected to flow through licensing/royalties from co-discovery and co-development agreements, milestone payments from therapeutic out-licensing, and future ingredient supply to consumer skincare brands. Pricing is quote-based and bespoke, with no public price list. The company has raised approximately $47.5M across a 2022 SEC-registered securities offering ($24.54M) and a 2022 Series A ($23M led by Safar Partners with Horizons Ventures and M Ventures). Customer concentration is structurally high given the platform's reliance on a small number of named enterprise partners across each vertical.

Short descriptiontext

Concerto Biosciences is a clinical-stage biotech that uses its proprietary kChip screening platform and kAI model — trained on 40M+ proprietary microbial interaction measurements — to discover live biotherapeutic and consumer health products across dermatology, women's health, food, and agriculture, commercialized through B2B co-development partnerships with biotech, consumer, and food-industry companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbial discovery platform, live biotherapeutic products, microbiome ingredient discovery, microbial interaction analysis, consumer health ingredients
Industry4 codes
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYAFAJAJAF
Protective Cultures & Biopreservation (Anti-Listeria, Anti-Mold, Shelf-Life Cultures)
Agriculture & Food Production/Food Ingredients & Additives/Cultures & Fermentation Ingredients (Starter Cultures, Probiotics, Yeast)
SECONDARYCRADAOAI
Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Laboratory Analytical Instruments3826
Product category
Microbial Drug Discovery
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Development and commercialization partnerships
TypeLicensing Royalties
Description

Concerto signs co-discovery and co-development agreements with industry partners (e.g., Sacco System) that combine platform access and IP with partners' domain expertise, microbial collections, and commercial reach. Revenue mechanics likely include upfront, milestone, and downstream commercialization terms typical of biotech co-development deals.

concertobio.com
2B2B ingredient supply (CB-0XX, postbiotic ferments)
TypeOne Time License
Description

Future/emerging revenue from supplying Concerto's proprietary microbe-based and postbiotic ferment ingredients to consumer skincare brands for deodorant, barrier, dandruff, and acne applications, enabled by partner go-to-market reach.

concertobio.com
3Therapeutic development and out-licensing (ENS-002)
TypeLicensing Royalties
Description

ENS-002 is being advanced via partner Fermata Dermatologics for atopic dermatitis; Concerto participates in therapeutic value capture through development collaborations and potential milestone/royalty economics as ENS-002 progresses through clinical trials.

concertobio.com
4Venture capital financing
TypeSubscription Recurring
Description

Pre-commercial biotech supplemented by venture capital funding, including a $23M Series A led by Safar Partners with Horizons Ventures and M Ventures in November 2022 and an SEC Form D securities offering totaling approximately $24.54M.

concertobio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom partnership-based pricing (quote-based)
ModelOther
Notes

Pricing and economic terms are negotiated individually with partners; no published price list, tiers, or unit pricing are disclosed. Partner inquiries directed to partnering@concertobio.com. Quote-based / Not publicly disclosed.

concertobio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1ENS-002
Description

Three-strain topical live biotherapeutic product (Ensemble No.2) that pacifies Staphylococcus aureus virulence, in clinical development for atopic dermatitis.

concertobio.com
+3 more records
Core offering1 text field

Concerto Biosciences operates a microbial intelligence platform that combines kChip, a patented microwell array that physically constructs and measures millions of microbial communities in parallel, with kAI, a proprietary AI model trained on those datasets to predict behavior of untested microbial combinations. This platform powers the discovery of microbe-based products across three segments: clinical-stage live biotherapeutics (ENS-002 for atopic dermatitis), discovery-stage live microbial candidates (ENS-003 for recurrent vaginal yeast infection), and a consumer skin health ingredient portfolio (CB-0XX including CB-002 postbiotic ferment) addressing malodor, barrier strength, acne, and dandruff. Revenue is generated primarily through B2B co-discovery, co-development, and licensing partnerships with biotech, biopharma, food, and consumer care companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 40M+ microbial communities constructed and measured (some references cite 50M+)
+3 more records
Product overview1 text field

Concerto Biosciences operates a single integrated platform-plus-product portfolio architecture anchored by its core discovery engine, kChip, and its proprietary AI model, kAI. kChip experimentally generates massive, high-quality datasets on microbial community behavior (>50M measurements), which train kAI to predict the behavior of untested microbe combinations. This intelligence platform feeds a portfolio of named products: the clinical-stage live biotherapeutic ENS-002 (topical three-strain product for atopic dermatitis, in development at Fermata Dermatologics); the discovery-stage ENS-003 (live microbial candidate for recurrent vaginal yeast infection); and the CB-0XX consumer skin health ingredient portfolio (including CB-002 postbiotic ferment), which addresses malodor, barrier strength, acne, and dandruff. The same platform is also deployed in co-discovery partnerships such as the Sacco System collaboration for next-generation food-grade microbial ingredients.

Product and service5 records
1kChip
CategoryMicrobial discovery platform
Description

MIT-developed, patented microwell array platform that physically constructs millions of miniature, defined microbial communities in parallel and captures direct functional readouts for every combination. Generates the empirical datasets that train kAI and underpin all of Concerto's microbe-based product discovery, solving the combinatorial bottleneck of conventional microbial screening. Made available to enterprise partners via co-discovery and co-development agreements.

2kAI
CategoryMicrobial ecology AI model
Description

Proprietary AI model of microbial ecology trained on kChip measurements (over 50M datapoints). Expands microbial interaction networks by predicting behavior of untested combinations, identifying synergistic and robust microbial communities for translation into real-world products. Powers hit generation across therapeutics, consumer products, and food applications, and is made available to enterprise partners as part of co-discovery and co-development agreements.

3ENS-002
CategoryClinical-stage live biotherapeutic product
Description

Topical, three-strain live biotherapeutic product (Ensemble No.2) composed of skin-derived, clonal, commensal, non-pathogenic bacterial strains delivered at equal ratio. Designed to inhibit Staphylococcus aureus proliferation and virulence in atopic dermatitis without disrupting beneficial skin microbes. FDA IND-cleared June 2024; Phase 1b positive topline results announced October 2025 showing zero drug-related adverse events, dose-dependent EASI improvement, and targeted S. aureus suppression. In development at partner Fermata Dermatologics for further clinical advancement.

4ENS-003
CategoryDiscovery-stage live microbial product
Description

Live microbial product candidate (Ensemble No.3) in kChip-based discovery for recurrent vulvovaginal candidiasis (vaginal yeast infection). Designed to inhibit Candida albicans virulence by reinforcing mechanisms of the natural protective vaginal microbiome, addressing a recurrent condition affecting over 1.5 million U.S. women with more than four symptomatic episodes per year.

5CB-0XX consumer skin health ingredient portfolio
CategoryConsumer skin health ingredient portfolio
Description

Portfolio of microbe-based ingredients for consumer skin health spanning solutions for malodor, skin barrier strength, acne, and dandruff. Discovered via kChip ultra-high-throughput microbial screening, with formulation types spanning live microbes, prebiotic nutrients, and postbiotic ferments. Includes CB-002, a postbiotic ferment formulated for consumer use targeting S. aureus-irritated skin. Supplied to consumer skincare and personal care brands for incorporation into retail products addressing deodorant, barrier support, dandruff, and acne care.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Concerto signed a development and commercialization agreement with Italian biotech group Sacco System on January 29, 2026 to advance next-generation microbial ingredient discovery for food, nutraceutical, pharmaceutical, and agro-veterinary applications. Sacco contributes its heritage library of food-grade cultures and applied food microbiology expertise; Concerto applies kChip technology to construct and measure millions of cocultures from Sacco's library and uses its kAI model to learn from those results. The collaboration aims to identify optimal strain synergies (1+1=3) for sustainable food production and deliver value to manufacturers and consumers. Concerto CEO Cheri Ackerman described it as setting a new standard for microbe-based product innovation.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-01-01
Description

kChip was prototyped by Jared Kehe, Cheri Ackerman, and others at MIT and the Broad Institute, then licensed by Concerto after the cofounders incorporated the company in 2020. Foundational research published in PNAS (https://www.pnas.org/content/116/26/12804/).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fermata Dermatologics is commercializing ENS-002, Concerto's three-strain live biotherapeutic for atopic dermatitis, currently in clinical testing. The Products page directs partners to fermatadermatologics.com for more information on the program.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage developer of defined live biotherapeutic products manufactured from clonal bacterial strains. Directly comparable to Concerto's ENS-002 program in modality (defined-strain consortia) and indication strategy (inflammatory diseases), making it the closest head-to-head peer.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company focused on inflammatory diseases including atopic dermatitis. Comparable as a peer in the live biotherapeutic space targeting the same dermatology indication as Concerto's ENS-002.

TypeDirect peer
Description

Developer of live bacterial therapeutic candidates for skin conditions, including acne and eczema. Comparable to Concerto on the dermatology microbiome indication axis and as a clinical-stage live biotherapeutics peer.

TypeDirect peer
Description

Skin microbiome company developing live and postbiotic products for acne and other skin conditions. Comparable to Concerto's CB-0XX consumer skin health ingredient portfolio and the broader skin-microbiome commercial thesis.

5Second Genome
TypeDirect peer
Description

Microbiome-based drug discovery company using high-throughput screening and computational biology to identify microbe-derived therapeutics. Comparable as a platform-driven microbiome drug discovery peer applying similar combinatorial screening to Concerto's kChip approach.

TypeBroad incumbent
Description

Pioneer and one of the most advanced microbiome therapeutics companies, with a recently approved live biotherapeutic and broader inflammatory/oncology pipeline. A larger incumbent offering overlapping capabilities in defined-strain microbiome therapeutics.

TypeBroad incumbent
Description

Clinical-stage biotechnology company with a microbiome platform (distinct from its virology portfolio) targeting inflammatory diseases. Operates in the same defined-strain live biotherapeutic category as Concerto with greater scale and a broader pipeline.

TypeEmerging player
Description

Developer of engineered microbiome-based therapeutics using phage-based delivery to modulate the microbiome. Comparable as a next-generation microbiome therapeutics peer with a more specialized (engineered) approach to microbial intervention.

9Novome Biotechnologies
TypeEmerging player
Description

Engineered microbial therapeutics company developing engineered consortia for hyperoxaluria and other indications. Comparable to Concerto on the engineered-microbial-consortium modality axis, though Novome's strain engineering is more genetically modified.

TypeBroad incumbent
Description

Ferring's microbiome therapeutics subsidiary and pioneer of fecal-microbiota-based live biotherapeutics with an FDA-approved product (Rebyota). A broad incumbent in the live biotherapeutic space against which Concerto's defined-strain approach competes on precision.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Concerto Biosciences

Microbial Drug Discoveryconcertobio.com

Concerto Biosciences is a clinical-stage biotech that uses its proprietary kChip screening platform and kAI model — trained on 40M+ proprietary microbial interaction measurements — to discover live biotherapeutic and consumer health products across dermatology, women's health, food, and agriculture, commercialized through B2B co-development partnerships with biotech, consumer, and food-industry companies.

What Concerto Biosciences does

Concerto Biosciences is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts, that measures, maps, and engineers microbial communities to develop therapies and consumer products across human health, food, and agricultural applications. The company's core asset is its integrated discovery platform comprising kChip, a patented MIT/Broad Institute-originated microwell array that physically constructs and measures millions of miniature microbial communities in parallel, and kAI, a proprietary artificial intelligence model trained on kChip-generated datasets to predict the behavior of untested microbial combinations. Together the platform has produced 40M+ microbial community measurements — including the 33M+ datapoint Skin Universe Project — forming the largest empirical microbial interaction dataset publicly described.

The company operates three product streams: ENS-002, a topical three-strain live biotherapeutic for atopic dermatitis that received FDA IND clearance in June 2024 and reported positive Phase 1b topline results in October 2025 (commercialized through partner Fermata Dermatologics); ENS-003, a discovery-stage live microbial candidate for recurrent vaginal yeast infection; and the CB-0XX consumer skin health ingredient portfolio addressing malodor, barrier strength, acne, and dandruff. Co-discovery and co-development agreements with partners such as Sacco System (food applications, signed January 2026) and Fermata Dermatologics (therapeutic development) provide commercial reach into consumer and biopharmaceutical channels.

Concerto's business model is a partnership-driven B2B platform play: revenue is expected to flow through licensing/royalties from co-discovery and co-development agreements, milestone payments from therapeutic out-licensing, and future ingredient supply to consumer skincare brands. Pricing is quote-based and bespoke, with no public price list. The company has raised approximately $47.5M across a 2022 SEC-registered securities offering ($24.54M) and a 2022 Series A ($23M led by Safar Partners with Horizons Ventures and M Ventures). Customer concentration is structurally high given the platform's reliance on a small number of named enterprise partners across each vertical.

Concerto Biosciences firmographics

Firmographics
Name
Concerto Biosciences
Legal name
Concerto Biosciences, Inc.
Website
https://concertobio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Concerto Biosciences is a clinical-stage biotech that uses its proprietary kChip screening platform and kAI model — trained on 40M+ proprietary microbial interaction measurements — to discover live biotherapeutic and consumer health products across dermatology, women's health, food, and agriculture, commercialized through B2B co-development partnerships with biotech, consumer, and food-industry companies.
Ownership category
akta.pro rank

Concerto Biosciences industry classification

Industry
Product category
Microbial Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Biological Products, (No Disgnostic Substances) (2836), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYAFAJAJAF
Protective Cultures & Biopreservation (Anti-Listeria, Anti-Mold, Shelf-Life Cultures)
Agriculture & Food Production/Food Ingredients & Additives/Cultures & Fermentation Ingredients (Starter Cultures, Probiotics, Yeast)
SECONDARYCRADAOAI
Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts)

Keywords

  • Microbial discovery platform
  • Live biotherapeutic products
  • Microbiome ingredient discovery
  • Microbial interaction analysis
  • Consumer health ingredients

Where Concerto Biosciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Concerto Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Development and commercialization partnerships: Concerto signs co-discovery and co-development agreements with industry partners (e.g., Sacco System) that combine platform access and IP with partners' domain expertise, microbial collections, and commercial reach. Revenue mechanics likely include upfront, milestone, and downstream commercialization terms typical of biotech co-development deals.
  2. B2B ingredient supply (CB-0XX, postbiotic ferments): Future/emerging revenue from supplying Concerto's proprietary microbe-based and postbiotic ferment ingredients to consumer skincare brands for deodorant, barrier, dandruff, and acne applications, enabled by partner go-to-market reach.
  3. Therapeutic development and out-licensing (ENS-002): ENS-002 is being advanced via partner Fermata Dermatologics for atopic dermatitis; Concerto participates in therapeutic value capture through development collaborations and potential milestone/royalty economics as ENS-002 progresses through clinical trials.
  4. Venture capital financing: Pre-commercial biotech supplemented by venture capital funding, including a $23M Series A led by Safar Partners with Horizons Ventures and M Ventures in November 2022 and an SEC Form D securities offering totaling approximately $24.54M.

Pricing tiers

ModelBillingPrice
Other—Custom partnership-based pricing (quote-based)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Concerto Biosciences product offering

Product offering

Core offering

Concerto Biosciences operates a microbial intelligence platform that combines kChip, a patented microwell array that physically constructs and measures millions of microbial communities in parallel, with kAI, a proprietary AI model trained on those datasets to predict behavior of untested microbial combinations. This platform powers the discovery of microbe-based products across three segments: clinical-stage live biotherapeutics (ENS-002 for atopic dermatitis), discovery-stage live microbial candidates (ENS-003 for recurrent vaginal yeast infection), and a consumer skin health ingredient portfolio (CB-0XX including CB-002 postbiotic ferment) addressing malodor, barrier strength, acne, and dandruff. Revenue is generated primarily through B2B co-discovery, co-development, and licensing partnerships with biotech, biopharma, food, and consumer care companies.

Product overview

Concerto Biosciences operates a single integrated platform-plus-product portfolio architecture anchored by its core discovery engine, kChip, and its proprietary AI model, kAI. kChip experimentally generates massive, high-quality datasets on microbial community behavior (>50M measurements), which train kAI to predict the behavior of untested microbe combinations. This intelligence platform feeds a portfolio of named products: the clinical-stage live biotherapeutic ENS-002 (topical three-strain product for atopic dermatitis, in development at Fermata Dermatologics); the discovery-stage ENS-003 (live microbial candidate for recurrent vaginal yeast infection); and the CB-0XX consumer skin health ingredient portfolio (including CB-002 postbiotic ferment), which addresses malodor, barrier strength, acne, and dandruff. The same platform is also deployed in co-discovery partnerships such as the Sacco System collaboration for next-generation food-grade microbial ingredients.

Differentiator

Problem solved

Functional benefit

Brands

  • ENS-002: Three-strain topical live biotherapeutic product (Ensemble No.2) that pacifies Staphylococcus aureus virulence, in clinical development for atopic dermatitis.
  • ENS-003
  • CB-0XX
  • CB-002

Products and services

  • kChip MIT-developed, patented microwell array platform that physically constructs millions of miniature, defined microbial communities in parallel and captures direct functional readouts for every combination. Generates the empirical datasets that train kAI and underpin all of Concerto's microbe-based product discovery, solving the combinatorial bottleneck of conventional microbial screening. Made available to enterprise partners via co-discovery and co-development agreements.
  • kAI Proprietary AI model of microbial ecology trained on kChip measurements (over 50M datapoints). Expands microbial interaction networks by predicting behavior of untested combinations, identifying synergistic and robust microbial communities for translation into real-world products. Powers hit generation across therapeutics, consumer products, and food applications, and is made available to enterprise partners as part of co-discovery and co-development agreements.
  • ENS-002 Topical, three-strain live biotherapeutic product (Ensemble No.2) composed of skin-derived, clonal, commensal, non-pathogenic bacterial strains delivered at equal ratio. Designed to inhibit Staphylococcus aureus proliferation and virulence in atopic dermatitis without disrupting beneficial skin microbes. FDA IND-cleared June 2024; Phase 1b positive topline results announced October 2025 showing zero drug-related adverse events, dose-dependent EASI improvement, and targeted S. aureus suppression. In development at partner Fermata Dermatologics for further clinical advancement.
  • ENS-003 Live microbial product candidate (Ensemble No.3) in kChip-based discovery for recurrent vulvovaginal candidiasis (vaginal yeast infection). Designed to inhibit Candida albicans virulence by reinforcing mechanisms of the natural protective vaginal microbiome, addressing a recurrent condition affecting over 1.5 million U.S. women with more than four symptomatic episodes per year.
  • CB-0XX consumer skin health ingredient portfolio Portfolio of microbe-based ingredients for consumer skin health spanning solutions for malodor, skin barrier strength, acne, and dandruff. Discovered via kChip ultra-high-throughput microbial screening, with formulation types spanning live microbes, prebiotic nutrients, and postbiotic ferments. Includes CB-002, a postbiotic ferment formulated for consumer use targeting S. aureus-irritated skin. Supplied to consumer skincare and personal care brands for incorporation into retail products addressing deodorant, barrier support, dandruff, and acne care.

Quantifiable outcome

  • 40M+ microbial communities constructed and measured (some references cite 50M+)
  • +3 more outcomes

Companies that use Concerto Biosciences

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Concerto Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Concerto Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Sacco SystemflagshipStrategic or Co-development Partner · 29 January 2026Concerto signed a development and commercialization agreement with Italian biotech group Sacco System on January 29, 2026 to advance next-generation microbial ingredient discovery for food, nutraceutical, pharmaceutical, and agro-veterinary applications. Sacco contributes its heritage library of food-grade cultures and applied food microbiology expertise; Concerto applies kChip technology to construct and measure millions of cocultures from Sacco's library and uses its kAI model to learn from those results. The collaboration aims to identify optimal strain synergies (1+1=3) for sustainable food production and deliver value to manufacturers and consumers. Concerto CEO Cheri Ackerman described it as setting a new standard for microbe-based product innovation.
  • MIT / Broad InstitutecoreTechnology or Integration · 1 January 2020kChip was prototyped by Jared Kehe, Cheri Ackerman, and others at MIT and the Broad Institute, then licensed by Concerto after the cofounders incorporated the company in 2020. Foundational research published in PNAS (https://www.pnas.org/content/116/26/12804/).
  • Fermata DermatologicscoreStrategic or Co-development PartnerFermata Dermatologics is commercializing ENS-002, Concerto's three-strain live biotherapeutic for atopic dermatitis, currently in clinical testing. The Products page directs partners to fermatadermatologics.com for more information on the program.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Concerto Biosciences competitors and assessment

Company assessment

Direct peers

  • Vedanta Biosciences: Clinical-stage developer of defined live biotherapeutic products manufactured from clonal bacterial strains. Directly comparable to Concerto's ENS-002 program in modality (defined-strain consortia) and indication strategy (inflammatory diseases), making it the closest head-to-head peer.
  • Siolta Therapeutics: Clinical-stage microbiome therapeutics company focused on inflammatory diseases including atopic dermatitis. Comparable as a peer in the live biotherapeutic space targeting the same dermatology indication as Concerto's ENS-002.
  • AOBiome: Developer of live bacterial therapeutic candidates for skin conditions, including acne and eczema. Comparable to Concerto on the dermatology microbiome indication axis and as a clinical-stage live biotherapeutics peer.
  • S-Biomedic: Skin microbiome company developing live and postbiotic products for acne and other skin conditions. Comparable to Concerto's CB-0XX consumer skin health ingredient portfolio and the broader skin-microbiome commercial thesis.
  • Second Genome: Microbiome-based drug discovery company using high-throughput screening and computational biology to identify microbe-derived therapeutics. Comparable as a platform-driven microbiome drug discovery peer applying similar combinatorial screening to Concerto's kChip approach.

Broad incumbents

  • Seres Therapeutics: Pioneer and one of the most advanced microbiome therapeutics companies, with a recently approved live biotherapeutic and broader inflammatory/oncology pipeline. A larger incumbent offering overlapping capabilities in defined-strain microbiome therapeutics.
  • Assembly Biosciences: Clinical-stage biotechnology company with a microbiome platform (distinct from its virology portfolio) targeting inflammatory diseases. Operates in the same defined-strain live biotherapeutic category as Concerto with greater scale and a broader pipeline.
  • Rebiotix (Ferring Pharmaceuticals): Ferring's microbiome therapeutics subsidiary and pioneer of fecal-microbiota-based live biotherapeutics with an FDA-approved product (Rebyota). A broad incumbent in the live biotherapeutic space against which Concerto's defined-strain approach competes on precision.

Emerging players

  • Eligo Bioscience: Developer of engineered microbiome-based therapeutics using phage-based delivery to modulate the microbiome. Comparable as a next-generation microbiome therapeutics peer with a more specialized (engineered) approach to microbial intervention.
  • Novome Biotechnologies: Engineered microbial therapeutics company developing engineered consortia for hyperoxaluria and other indications. Comparable to Concerto on the engineered-microbial-consortium modality axis, though Novome's strain engineering is more genetically modified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Concerto Biosciences social profiles

Digital presence

Concerto Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Concerto Biosciences leadership team

Management profile

Number of profiles

Profiles11 records

Concerto Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Concerto Biosciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Concerto Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concerto Biosciences

What does Concerto Biosciences do?

Concerto Biosciences operates a microbial intelligence platform that combines kChip, a patented microwell array that physically constructs and measures millions of microbial communities in parallel, with kAI, a proprietary AI model trained on those datasets to predict behavior of untested microbial combinations. This platform powers the discovery of microbe-based products across three segments: clinical-stage live biotherapeutics (ENS-002 for atopic dermatitis), discovery-stage live microbial candidates (ENS-003 for recurrent vaginal yeast infection), and a consumer skin health ingredient portfolio (CB-0XX including CB-002 postbiotic ferment) addressing malodor, barrier strength, acne, and dandruff. Revenue is generated primarily through B2B co-discovery, co-development, and licensing partnerships with biotech, biopharma, food, and consumer care companies.

Is Concerto Biosciences a public or private company?

Concerto Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Concerto Biosciences founded?

Concerto Biosciences was founded in 2020. It employs 11 to 50 people.

Where is Concerto Biosciences based?

Concerto Biosciences is headquartered in Cambridge, United States, in the North America region.

How does Concerto Biosciences make money?

Four revenue lines are on record. Development and commercialization partnerships are the primary driver. The others are B2B ingredient supply (CB-0XX, postbiotic ferments), therapeutic development and out-licensing (ENS-002) and venture capital financing.

Who are Concerto Biosciences's main competitors?

Direct peers on record are Vedanta Biosciences, Siolta Therapeutics, AOBiome, S-Biomedic and Second Genome. Broad incumbents are Seres Therapeutics, Assembly Biosciences and Rebiotix (Ferring Pharmaceuticals). Emerging players are Eligo Bioscience and Novome Biotechnologies.

Does Concerto Biosciences have an API?

No public API is recorded for Concerto Biosciences.

What industry is Concerto Biosciences in?

Concerto Biosciences's product category is Microbial Drug Discovery. Its primary akta.pro industry code is HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms, with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GreyBSkin Microbiome Claims: Regulatory Risks for Skincare BrandsOver 40% of 2024 skincare launches featured microbiome-related ingredients, yet approximately 90% of products labeled as probiotic actually contain postbiotics with no live bacteria, creating significant regulatory exposure as FDA enforcement under MoCRA intensifies in 2025 and EU truth-in-labeling frameworks tighten. The article identifies six technology categories driving the skin microbiome innovation landscape—postbiotics, live biotherapeutic products, advanced delivery systems, targeted antimicrobials, multi-biotic systems, and AI-driven personalization—with specific company programs including Concerto Biosciences' ENS-002 (FDA IND-cleared), L'Oréal's acquisition of Lactobio, and Phyla's Sephora phage launch. Industry analysts recommend that R&D teams prioritize postbiotic development with rigorous clinical substantiation, invest in encapsulation technology to bridge the gap between lab performance and mass-market viability, and treat regulatory strategy as a design input rather than a post-launch concern.AijournConcerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient DiscoveryConcerto Biosciences has signed a development and commercialization agreement with Sacco System to advance next-generation microbial ingredient discovery for food and health applications. Sacco System will contribute its heritage library of food-grade cultures while Concerto applies its kChip technology and AI platform (kAI) to systematically study microbial interactions and identify optimal strain synergies. The collaboration aims to develop novel ingredients composed of synergistically interacting microbes with desirable functional properties to deliver value to food manufacturers and consumers through sustainable production.PR NewswireConcerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient DiscoveryConcerto Biosciences and Sacco System signed a development and commercialization agreement to develop novel microbial ingredients using advanced AI and microbiology technologies. The collaboration aims to identify microbial synergies for applications in food, health, and wellness industries.PR NewswireConcerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic DermatitisConcerto Biosciences announced positive results from its Phase 1b clinical trial of ENS-002, a topical biotherapeutic for atopic dermatitis, which demonstrated safety and efficacy in reducing eczema symptoms and suppressing S. aureus without harming beneficial skin microbes. The trial involved eight participants and showed durability of improvement with no adverse events. The company plans further studies to evaluate safety, efficacy, and maintenance dosing.PR NewswireConcerto Biosciences Announces Appointment of Dr. Stewart Campbell to Board of DirectorsConcerto Biosciences announced the appointment of Dr. Stewart Campbell to its Board of Directors as an Independent Director, effective January 29, 2025. Dr. Campbell brings 30 years of therapeutic development experience, having most recently served as CEO of Axial Therapeutics since 2021 and previously as VP of R&D since 2017, with prior roles at Boehringer Ingelheim, Corden Pharma, Surface Logix, and Insmed. He has played a role in developing nine clinical-stage drug candidates and is a co-inventor on 25 issued patents.AvEpisode #60: Meet the Start-up Focused on Microbe-techAlumni Ventures hosted an episode of its Tech Optimist Podcast featuring Cheri Ackerman, co-founder and CEO of Concerto Biosciences, to discuss the company's microbial technology. Concerto Biosciences is utilizing its proprietary kChip platform to test millions of microbial combinations for developing treatments in health and agriculture, specifically highlighting clinical trials for eczema and vaginal yeast infections.PR NewswireConcerto Biosciences Receives FDA Investigational New Drug Clearance for Live Biotherapeutic Product to Treat Atopic DermatitisConcerto Biosciences, a Cambridge-based biotechnology company, has received FDA Investigational New Drug clearance to initiate Phase 1 first-in-human trials for ENS-002, an investigational live biotherapeutic product to treat atopic dermatitis. The product consists of a synergistic combination of three non-pathogenic, skin-derived bacterial strains identified through the company's proprietary kChip screening technology, which generated over 6 million microbial combinations to find strains that suppress disease-causing S. aureus. The company has progressed from initial concept in 2020 to FDA clinical trial clearance in 2024, representing its first product to advance from discovery into clinical development.VentureRadarTop dermatology start-upsNumerous start-ups focused on dermatological innovation and solutions have emerged, including Concerto Biosciences, VIATRIS, and Vial, all founded in 2020 and based in the USA. These companies are developing a range of therapeutic products, technologies, and approaches, highlighting the growing interest in dermatology as a specialized field within healthcare. The article showcases a variety of companies from different countries, indicating a broader trend in the growth of the dermatological market.VentureRadarTop equipment rental start-upsThe article presents a curated list of various privately held start-ups, primarily in the healthcare technology and equipment rental sectors, detailing their founding years, core business focus, and websites. It highlights companies such as Delfina, Cellinfinity Bio, Concerto Biosciences, and Moxion Power, among others, providing brief descriptions of their proprietary technologies or market positions. The content serves as an informational directory rather than reporting on a specific corporate event or transaction.PR NewswireConcerto Biosciences Co-Founder and CEO Cheri Ackerman selected as an Ernst & Young Entrepreneur Of The Year® 2023 New England finalistConcerto Biosciences announced that Co-Founder and CEO Cheri Ackerman has been selected as a finalist for the Ernst & Young Entrepreneur Of The Year® 2023 New England Award, now in its 37th year. The company, a biotechnology firm that launched in 2020, has developed a patented kChip platform capable of measuring over 6 million microbial interactions and completed a $23 million Series A fundraise last November. Regional award winners will be announced on June 7, 2023, with national winners considered later for the EY World Entrepreneur Of The Year™ Award in June 2024.